Modern trends in the treatment of diabetic nephropathy

Česká verzia

Authors: Peter Ponťuch
Authors place of work: IV. interná klinika LF UK a UNB, Nemocnica sv. Cyrila a Metoda, Bratislava
Published in the journal: Forum Diab 2019; 8(2): 111-115
Category: Review Article

Summary

Long-term optimal glycemic control reduces the risk or slows the progression of chronic kidney disease. Some sodium-glucose cotransporter 2 inhibitors and glucagon-like peptid 1 receptor agonists have shown to reduce the risk of chronic kidney disease and cardiovascular events in patients with type 2 diabetes. Optimal control of blood pressure, based on angiotensin converting enzyme inhibitor (ACEI), or angiotensin receptor blocker (ARB), reduces the risk and slows the progression of chronic kidney disease. Dual combination of ACEI and ARB should not be given due to adverse side effects, mainly hyperkalemia and acute kidney injury. ACEI or ARB is not recommended for the primary prevention of chronic kidney disease in patients with diabetes who have normal albuminuria, normal blood pressure and normal glomerular filtration rate. Target blood pressure values should be individualized taking into account patient´s age and comorbidities. Ongoing clinical studies with finerenone and atrasentan are aimed at renal outcomes in patients with diabetes.

Keywords:

glucagon-like peptid 1 receptor agonists – renin-angiotensin system blockade – sodium-glucose cotransporter 2 inhibitors – the treatment of diabetic nephropathy

Zdroje

de Boer IH, Rue TC, Cleary PA et al. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: Ananalysis of Diabetes Control and Complications Trial / Epidemiology of Diabetes Interventions and Complications Cohort. Arch Intern Med 2011; 171(5): 412–420. Dostupné z DOI: <http://dx.doi.org/10.1001/archinternmed.2011.16>.
Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359(15): 1577–1589. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0806470>.
Zoungas S, Arima H, Gerstein HC et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 2017; 5(6): 431–437. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(17)30104–3>.
[Guideline development group]. Clinical practice guidelines on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR<45 ml/min). Nephrol Dial Transplant 2015; 30(Suppl 2): ii1-ii142. Dostupné z DOI: <http://dx.doi.org/10.1093/ndt/gfv100>.
American Diabetes Association. Standards of medical care in diabetes – 2019. Microvascular complications and foot care. Diabetes Care 2019; 42(Suppl 1): S124-S138. Dostupné z DOI: <http://dx.doi.org/10.2337/dc19-S011>.
Zinman B, Wanner C, Lachin JM et al. [EMPA-REG OUTCOME Investigators]. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med 2015; 373(22): 2117–2128. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1504720>.
Wanner C, Inzucchi SE, Lachin JM et al. [EMPA-REG OUTCOME Investigators]. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375(4): 323–334. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1515920>.
Neal B, Perkovic V, Mahaffey KW et al. [CANVAS Program Collaborative Group]. Canagliglozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377(7): 644–657. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1611925>.
Heerspink HJL, Desai M, Jardine M et al. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 2017; 28(1): 368–375. Dostupné z DOI: <http://dx.doi.org/10.1681/ASN.2016030278>.
Perkovic V, Jardine MJ, Neal B et al. [CREDENCE Trial Investigators]. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1811744>.
Marso SP, Daniels GH, Brown-Frandsen K et al. [LEADER Trial Investigators]. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375(4): 311–322. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1603827>.
Mann JFE, Ørsted DD, Brown-Frandsen K et al. [LEADER Steering Committee and Investigators]. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017; 377(9): 839–848. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1616011>.
Rosenstock J, Perkovic V, Johansen OE et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA randomized clinical trial. JAMA 2019; 321(1): 69–79. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2018.18269>.
Cushman WC, Evans GW, Byington RP et al. [ACCORD Study Group]. Effects of intensive blood pressure control in type 2 diabetes mellitus. New Engl J Med 2010; 362(17): 1575–1585. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1001286>.
Fried LF, Enabuele N, Zhang JH,et al. [VA NEPHRON-D Investigators]. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369(20): 1892–1903. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1303154>. Erratum in N Engl J Med 2014; 158: A7255.
Makani H, Bangalore S, Desouza K et al. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. Br Med J 2013; 346: f360. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.f360>.
Haller H, Ito S, Izzo J et al. [ROADMAP Trial Investigators]. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364(10): 907–917. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1007994>.
Bakris G, Agarwal R, Chan JC et al. [ARTS-DN Study Group]. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 2015; 314(9): 884–894. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2015.10081>.
de Zeeuw D, Coll B, Andress D et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol 2014; 25(5): 1083–1093. Dostupné z DOI: <http://dx.doi.org/10.1681/ASN.2013080830>.